 Ovid Therapeutics Inc. OVID, a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration FDA has granted Rare Pediatric Disease Designation to OV101 gaboxadol for the treatment of Angelman syndrome. OV101 is believed to be the only delta δ-selective GABAA receptor agonist in development and is currently being evaluated in the Companys pivotal Phase 3 NEPTUNE trial in Angelman syndrome, with topline results expected in the fourth quarter of 2020. The FDA has previously granted Orphan Drug and Fast Track designations for OV101 for the treatment of Angelman syndrome. 